Literature DB >> 8039593

High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop.

R S Schmidli1, P G Colman, E Bonifacio, G F Bottazzo, L C Harrison.   

Abstract

Glutamic acid decarboxylase antibodies (GADAbs) are being increasingly used in clinical and research programs for the prediction and classification of insulin-dependent diabetes mellitus (IDDM). A number of different assay formats for the measurement of GADAbs have been reported, but the degree of concordance between assays is unknown. In this study, GADAbs were measured on 16 coded sera in 34 assays to examine concordance between GADAb assays and establish the feasibility of an international GADAb standard of measurement unit. The 16 lyophilized coded samples consisted of sera from healthy control subjects (n = 2), IDDM patients (n = 3), a patient with polyendocrine autoimmunity (n = 1), and duplicate dilutions of plasmapheresis serum from a patient with stiff-man syndrome (SMS). A high level of concordance was found in the ranking of GADAb levels (P = 0.99, Friedman's test) in the samples. Thirteen (38%) assays could reproducibly distinguish dilutions of SMS serum and detect GADAbs in all IDDM and polyendocrine autoimmunity sera tested. Although assessed on only four samples, disease specificity was 100% in 29 assays. The majority of assays that immunoprecipitated radiolabeled GAD gave high results for sensitivity and specificity. Enzyme-linked immunosorbent assays and assays using immunofluorescence were generally less sensitive. Several assays, in particular those measuring GAD enzymatic activity immunoprecipitated in fluid phase from rat brain homogenate, showed a prozone-like phenomenon in the SMS dilution curve. Interpolation of results from a standard curve into workshop units resulted in relatively low scatter in samples with lower levels of GADAbs. Hence, the use of an international reference serum to enable comparison of results between laboratories appears feasible.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039593     DOI: 10.2337/diab.43.8.1005

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  15 in total

1.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  HLA class II is associated with the frequency of glutamic acid decarboxylase M(r) 65,000 autoantibodies in Japanese patients with insulin-dependent diabetes mellitus.

Authors:  A Kasuga; A Falorni; T Maruyama; Y Ozawa; C E Grubin; K Matsubara; I Takei; T Saruta; A Scheynius; A Lernmark
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

3.  Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia.

Authors:  Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

4.  Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM.

Authors:  A Falorni; M Ackefors; C Carlberg; T Daniels; B Persson; J Robertson; A Lernmark
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

5.  Association between HLA and islet cell antibodies in diabetic patients with a mitochondrial DNA mutation at base pair 3243.

Authors:  T Kobayashi; Y Oka; H Katagiri; A Falorni; A Kasuga; I Takei; K Nakanishi; T Murase; K Kosaka; A Lernmark
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

Review 6.  Autoantibodies in insulin-dependent diabetes mellitus.

Authors:  E Bosi; E Bonifacio
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

7.  Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes.

Authors:  H J Aanstoot; S M Kang; J Kim; L A Lindsay; U Roll; M Knip; M Atkinson; P Mose-Larsen; S Fey; J Ludvigsson; L Landin; J Bruining; N Maclaren; H K Akerblom; S Baekkeskov
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

8.  Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children.

Authors:  W A Hagopian; C B Sanjeevi; I Kockum; M Landin-Olsson; A E Karlsen; G Sundkvist; G Dahlquist; J Palmer; A Lernmark
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.

Authors:  S E Monstad; A Storstein; A Dørum; A Knudsen; P E Lønning; H B Salvesen; J H Aarseth; C A Vedeler
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

10.  Regulated exocytosis of GABA-containing synaptic-like microvesicles in pancreatic beta-cells.

Authors:  Matthias Braun; Anna Wendt; Bryndis Birnir; Jonas Broman; Lena Eliasson; Juris Galvanovskis; Jesper Gromada; Hindrik Mulder; Patrik Rorsman
Journal:  J Gen Physiol       Date:  2004-02-09       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.